Currently, CD19-targeted CAR-T therapies have been approved by the U.S. Food and Drug Administration (FDA) as monotherapy for treating relapsed/refractory aggressive B-cell lymphomas and indolent B cell lymphomas. The gene discussed is CD19; the disease is B-cell non-Hodgkin lymphoma.